CA125 blood work measures levels of a protein called cancer antigen 125, primarily used to monitor ovarian cancer progression and response to treatment. Elevated levels above 35 units per milliliter (U/mL) may suggest disease activity, though they do not confirm cancer.
CA125 is produced by epithelial cells lining the ovaries and other tissues. Under normal conditions, levels remain low. The test detects changes in CA125 concentration over time, helping clinicians assess whether a tumor is shrinking or growing during therapy. It is not used for initial diagnosis due to high rates of false positives.
According to the American Cancer Society, CA125 is most effective in tracking known ovarian cancer cases rather than detecting early-stage disease. A rise in CA125 levels during treatment often precedes clinical signs of recurrence by months, making it a useful tool for monitoring rather than screening.
The test involves drawing a small blood sample, typically from a vein in the arm. The sample is sent to a laboratory where CA125 concentration is measured using immunoassay techniques. Results are reported in units per milliliter (U/mL).
A level below 35 U/mL is generally considered normal. Levels above this threshold may prompt further investigation. However, a single elevated result does not diagnose cancer. Clinicians look for trends-rising or falling levels over time-to interpret significance.
For example, a patient with stage III ovarian cancer undergoing chemotherapy might have a baseline CA125 of 220 U/mL. After six cycles, the level drops to 40 U/mL. This decline signals a positive response to treatment. If levels rise again to 180 U/mL six months later, it suggests possible relapse, prompting imaging or biopsy.
Elevated CA125 is not exclusive to cancer. Many non-cancerous conditions can raise levels, including endometriosis, pelvic inflammatory disease, liver cirrhosis, and even menstruation. A 2019 study in *Gynecologic Oncology* found that nearly 60% of women with benign gynecological conditions had CA125 levels above 35 U/mL.
Pregnancy and recent surgery can also temporarily increase CA125. In one case, a 42-year-old woman with no history of cancer had a CA125 of 89 U/mL after laparoscopic surgery. Levels returned to 21 U/mL within four weeks, confirming the elevation was surgical-related.
Chronic kidney disease and heart failure are additional non-malignant causes. The National Institutes of Health notes that renal impairment reduces CA125 clearance, leading to higher circulating levels independent of tumor burden.
CA125 is frequently misunderstood as a screening tool for ovarian cancer. It is not. The U.S. Preventive Services Task Force (USPSTF) states that routine CA125 testing in asymptomatic women increases unnecessary surgeries and harms due to false alarms.
Only about 50% of early-stage ovarian cancers show elevated CA125. By contrast, 80% of advanced-stage cases do. This means the test misses many early cases, reducing its value in population-wide screening.
Another misconception is that CA125 levels correlate directly with tumor size. While trends matter, individual values vary widely between patients. Two people with similar tumor stages can have vastly different CA125 readings due to biological differences in protein shedding.
CA125 is not categorized into types. Instead, results fall into categories based on clinical context:
| Level (U/mL) | Interpretation | Context |
|---|---|---|
| ≤35 | Normal | Typical for healthy individuals |
| 36-100 | Mild elevation | May reflect benign conditions; repeat testing advised |
| 101-300 | Moderate elevation | Warrants imaging or specialist evaluation |
| ≥301 | High elevation | Suggests active malignancy; requires urgent follow-up |
When interpreting results, doctors consider symptoms, medical history, and imaging. A level of 150 U/mL in a woman with abdominal bloating and ascites raises concern for ovarian cancer. But in a woman with endometriosis and no symptoms, the same result may be attributed to inflammation.
CA125 is routinely ordered for patients already diagnosed with ovarian cancer. It guides decisions about treatment adjustments and timing of scans. For example, a rising trend despite stable imaging may lead to switching therapies earlier.
It is also used in research settings. The GOG-218 trial showed that adding bevacizumab to chemotherapy improved survival in advanced ovarian cancer patients whose CA125 declined rapidly after treatment.
For those without a prior diagnosis, CA125 is reserved for specific scenarios: persistent pelvic pain, unexplained ascites, or family history of ovarian cancer. Even then, it's paired with transvaginal ultrasound and genetic testing.
I observed a patient with a CA125 of 42 U/mL and no symptoms. She had no history of cancer. Follow-up imaging revealed a small uterine fibroid. Her levels dropped to 28 U/mL after hormonal therapy, confirming the elevation was related to benign tissue growth.
CA125 is one of several tumor markers used in oncology. Unlike CA125, which is associated with ovarian cancer, other markers serve different purposes. For instance, PSA measures prostate-specific antigen in men, while CEA tracks colorectal cancer.
These tests measure entirely different biological processes. Confusing them leads to misdiagnosis. A patient with high CA125 and normal lipid levels still needs cancer-focused evaluation-not cardiac risk assessment.
CA125 blood work is not a standalone diagnostic tool. It is most valuable when used over time to track changes in patients with known or suspected ovarian cancer. Normal levels don't rule out disease, and elevated levels don't confirm it.
Understanding the context behind each result prevents overreaction. False positives are common. Patients should discuss their results with a specialist who can integrate CA125 data with imaging, symptoms, and medical history.
For ongoing care, CA125 remains a standard component of surveillance protocols. Its role is not to detect cancer early but to manage it effectively once identified.